| Therapeutic Area |
Product (Phase) |
Product Class/MOA |
Target Disease |
| Cardiovascular |
CS-8635
(NDA filed) |
ARB/CCB/Diuretic |
Hypertension |
edoxaban
(Phase 3) |
Factor Xa Inhibitor |
AF/Stroke Prevention, VTE/DVT,PE |
CS-747/
prasugrel1
(Phase 3) |
P2Y12 Inhibitor |
ACS-Medically Managed |
| Oncology |
tigatuzumab
(Phase 2) |
DR5 Antibody |
Solid Tumors |
ARQ-1972
(Phase 2) |
c-met Inhibitor |
Solid Tumors |
CS-7017
(Phase 2) |
PPAR-γ Agonist |
Solid Tumors |
U3-12873
(Phase 1) |
HER-3 Antibody |
Solid Tumors |
| Immunology |
CS-0777
(Phase 1) |
S1P1 Agonist |
Multiple Sclerosis |
|
|
